As demand for GLP-1 weight-loss drugs propels the biotech industry to unprecedented levels, investors are discovering that the sector offers diverse opportunities beyond these popular treatments. Salveen Richter, the lead analyst for U.S. biotechnology at Goldman Sachs, shared insights on overlooked biotech investments in a recent discussion with Market Domination.
In a current market climate where healthcare investments often favor defensive sectors, biotech presents both defensive and growth-oriented opportunities. Richter highlighted that a potential rate cut could benefit the sector, particularly in a recessionary environment where investors seek stability in large-cap, quality-focused companies. She suggests that firms like Amgen (AMGN) are well-positioned for such conditions. Beyond its GLP-1 weight-loss products, Amgen is advancing its research into cancer and autoimmune diseases and is utilizing artificial intelligence in its genetic medicine initiatives.
Richter also emphasized Vertex Pharmaceuticals (VRTX) as a promising investment. Vertex is not only expanding its dominance in cystic fibrosis treatments but is also developing a non-opioid pain management option. Additionally, the company is venturing into cancer therapies and autoimmune disorders. According to Richter, Vertex’s innovation and potential for sustainable growth make it a compelling choice. Both Amgen and Vertex stand out for their strategic diversification and leading-edge approaches in their respective fields.
